Abstract
It is largely taken for granted that differential abundance analysis is, by default, the best first step when analyzing genomic data. We argue that this is not necessarily the case. In this article, we identify key limitations that are intrinsic to differential abundance analysis: it is (a) dependent on unverifiable assumptions, (b) an unreliable construct, and (c) overly reductionist. We formulate an alternative framework called ratio-based biomarker analysis which does not suffer from the identified limitations. Moreover, ratio-based biomarkers are highly flexible. Beyond replacing DAA, they can also be used for many other bespoke analyses, including dimension reduction and multi-omics data integration.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
